SCHEMBL1140069

SCHEMBL1140069

N#CCNC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2cccc3ccccc23)C[C@H]1C(=O)N1CCOCC1

nearest known ligand 0.77

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSS P25774 20/20 0.77
CTSB P07858 9/20 0.74
CTSL P07711 7/20 0.74
CTSK P43235 5/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13021349 1.00 CTSS (0.77) CTSSCTSBCTSLCTSK
SCHEMBL1139545 0.87 CTSS (1.00) CTSSCTSBCTSLCTSK
SCHEMBL1139388 0.85 CTSS (1.00) CTSSCTSBCTSLCTSK
SCHEMBL1139147 0.85 CTSS (1.00) CTSSCTSBCTSLCTSK
SCHEMBL15654446 0.82 CTSS (0.56) CTSSCTSBCTSLCTSK
SCHEMBL7806564 0.81 CTSS (0.51) CTSSCTSBCTSLCTSK
SCHEMBL1139786 0.81 CTSS (0.81) CTSSCTSBCTSLCTSK
SCHEMBL1139049 0.81 CTSS (0.84) CTSSCTSBCTSLCTSK
SCHEMBL12863689 0.80 CTSS (0.69) CTSSCTSBCTSLCTSK
SCHEMBL1137913 0.80 CTSS (0.69) CTSSCTSBCTSLCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP claimed
EP-2440521-A1 NOVEL CYCLOPENTANE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-04-18 EP claimed
US-7893099-B2 Cyclopentane derivatives HOFFMAN-LA ROCHE INC. (US) 2011-02-22 US claimed
WO-2010142650-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 WO claimed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US claimed
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP disclosed
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP disclosed
EP-2440521-A1 NOVEL CYCLOPENTANE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-04-18 EP disclosed
US-7893099-B2 Cyclopentane derivatives HOFFMAN-LA ROCHE INC. (US) 2011-02-22 US disclosed
US-7893099-B2 Cyclopentane derivatives HOFFMAN-LA ROCHE INC. (US) 2011-02-22 US disclosed
US-7893099-B2 Cyclopentane derivatives HOFFMAN-LA ROCHE INC. (US) 2011-02-22 US disclosed
WO-2010142650-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 WO disclosed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES TBXA2R, ADORA1, CNR1 CTSS 2367/4885CTSB 1975/4885CTSL 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.